Clinical Trial Update: Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability study of CFT7455 in relapsed/refractory non-Hodgkin's lymphoma and multiple myeloma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• CFT7455 (CFT7455)

Snippet

Sponsor: C4 Therapeutics, Inc. | Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin's | Phase 1 | Status: ACTIVE_NOT_RECRUITING